Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02ALD
|
||||
Former ID |
DIB001242
|
||||
Drug Name |
NOLOMIROLE HYDROCHLORIDE
|
||||
Synonyms |
CHF-1035; Nolomirole hydrochloride < Prop INNM >; Rac-5,6-Diisobutyryloxy-2-(methylamino)-1,2,3,4-tetrahydronaphthalene hydrochloride
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Heart failure [ICD9: 428; ICD10:I50] | Discontinued in Phase 3 | [545464] | ||
Structure |
Download2D MOL |
||||
Formula |
C19H28ClNO4
|
||||
Canonical SMILES |
CC(C)C(=O)OC1=C(C2=C(CC(CC2)NC)C=C1)OC(=O)C(C)C.Cl
|
||||
InChI |
1S/C19H27NO4.ClH/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4;/h6,9,11-12,14,20H,7-8,10H2,1-5H3;1H
|
||||
InChIKey |
TWTMQRXNAZGSCE-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [526875] | |
D(2) dopamine receptor | Target Info | Agonist | [526875], [551871] | ||
PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Dopamine receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
WikiPathways | Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
Platelet Aggregation (Plug Formation) | |||||
Integration of energy metabolism | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
GPCR downstream signaling | |||||
Nicotine Activity on Dopaminergic Neurons | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.